article thumbnail

Can App Data Link Sleep and Chronic Disease?; AI Model to Manage Diabetes

Med Page Today

(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.

article thumbnail

Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes

Cardiovascular Diabetology

Diabetes mellitus is a chronic disease which is detrimental to cardiovascular health, often leading to secondary microvascular complications, with huge global health implications. Therapeutic interventions tha.

Diabetes 102
article thumbnail

Physiology Friday #228: Identifying Sleep Patterns that Influence Chronic Disease Risk

Physiologically Speaking

We talk about the ketogenic diet as a metabolic therapy for type 1 diabetes. Dozens if not hundreds of (albeit observational) studies have linked a short sleep duration to a number of health conditions including type 2 diabetes and cardiovascular disease. Welcome to the Physiology Friday newsletter. hours per night.

article thumbnail

New initiative focuses on oral health clinicians in prevention and early detection of heart disease

American Heart News - Heart News

Research shows that chronic gum inflammation may be associated with other chronic diseases including coronary artery disease and diabetes.[1] DALLAS, JANUARY 16, 2024 — A patient’s oral health can be an indicator of overall health and well-being.

article thumbnail

The Management of Chronic Disease

Dr. Sanjay Gupta

The principles that I am discussing here can be applied to all chronic diseases. The diagnosis of any chronic long-term disease can be a traumatic and life-changing experience for a patient. For the patient, it should be about instilling gratitude in their lives. I hope you found this useful.

article thumbnail

Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration

Frontiers in Cardiovascular Medicine

Case presentation The patient was an obese 72 years old man, past smoker, diagnosed with ischaemic heart disease, type 2 diabetes mellitus and lipid metabolism disorder. Statin treatment was not implemented because of chronic myasthenia gravis and PCSK9i monotherapy [Repatha (evolucamab), 140 mg] was implemented to treat dyslipidaemia.

article thumbnail

Decoding Longevity. How To Not Die. Young

Dr. Paddy Barrett

As I have written about before , the risk of all three conditions mentioned above, which are leading causes of death, are driven by poor metabolic health ranging from insulin resistance to the more extreme phenotype, type 2 diabetes. Those in the ‘Ideal’ lifestyle category had 84% fewer metabolic diseases.

Cancer 72